Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $35.91.

SNDX has been the subject of several research reports. Wall Street Zen upgraded Syndax Pharmaceuticals to a “sell” rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank lifted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a “sector perform” rating in a research note on Tuesday, May 6th. Finally, Citigroup lowered their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals during the 4th quarter valued at $26,000. Quarry LP purchased a new stake in shares of Syndax Pharmaceuticals during the 1st quarter valued at $25,000. Virtus ETF Advisers LLC grew its stake in shares of Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after buying an additional 827 shares during the period. Cape Investment Advisory Inc. grew its stake in shares of Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after buying an additional 3,927 shares during the period. Finally, KBC Group NV grew its stake in shares of Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after buying an additional 3,559 shares during the period.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $9.85 on Tuesday. Syndax Pharmaceuticals has a 1 year low of $8.58 and a 1 year high of $25.07. The company has a market capitalization of $847.56 million, a P/E ratio of -2.71 and a beta of 0.82. The business has a 50 day moving average price of $11.76 and a 200 day moving average price of $13.61.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. The company’s revenue for the quarter was up 1900.0% on a year-over-year basis. As a group, research analysts expect that Syndax Pharmaceuticals will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).